 DANBURY, Conn., June 16, 2021 GLOBE NEWSWIRE -- MannKind Corporation Nasdaq: MNKD and United Therapeutics Corporation Nasdaq: UTHR reached a major milestone today with the announcement that the U.S. Food and Drug Administration FDA accepted for priority review of the New Drug Application NDA for Tyvaso DPITM inhaled treprostinil for the treatment of pulmonary arterial hypertension PAH and pulmonary hypertension associated with interstitial lung disease PH-ILD. The development marks the second compound formulated with MannKinds Technosphere technology to be reviewed by the FDA, which is expected to be complete in October 2021. The FDA has also indicated that they have not identified any potential review issues at this time. 